Dr. Dr. med. Sergio Castro-Gomez
Institute of Physiology II & Center for Neurology, Department of Neurodegenerative Diseases / Neurology
sergio.castro-gomez@ukbonn.de View member: Dr. Dr. med. Sergio Castro-Gomez
Cell reports. Medicine
The NLR family pyrin domain containing protein 3 (NLRP3) inflammasome orchestrates neuroinflammation, but its role in traumatic brain injury (TBI) and the therapeutic value of pharmacological inhibition remain incompletely defined. Using Nlrp3-deficient mice and two novel orally bioavailable selective antagonists (NP3-253 and NP3-361), we investigate NLRP3-dependent mechanisms of post-traumatic neuroinflammation and functional recovery. After controlled cortical impact, NLRP3 inflammasome components, pro-inflammatory genes, and mediators are robustly upregulated during the first post-injury week. Genetic Nlrp3 deletion and post-TBI NP3-253 treatment preserve microglial architecture and reduce aggregation and redistribution of the inflammasome adaptor apoptosis-associated speck-like protein containing a CARD (ASC), while post-TBI NP3-253 and NP3-361 therapeutically accelerate neurological recovery during treatment. Longitudinal intravital imaging shows that pre-TBI NLRP3 inhibition with NP3-361 constrains post-traumatic microglial activation in vivo. These findings establish NLRP3 as a driver of post-traumatic microglial morphodynamics and support selective NLRP3 inhibition as a promising strategy to improve neurological outcomes after TBI.
Copyright © 2026. Published by Elsevier Inc.
PMID: 43063935
Institute of Physiology II & Center for Neurology, Department of Neurodegenerative Diseases / Neurology
sergio.castro-gomez@ukbonn.de View member: Dr. Dr. med. Sergio Castro-GomezInstitute of Innate Immunity
Felix.Meissner@ukbonn.de View member: Prof. Dr. Felix MeissnerInstitute of Innate Immunity
eicke.latz@uni-bonn.de View member: Prof. Dr. Eicke LatzInstitute of Neurology
View member: Prof. Dr. Michael Heneka